Westar Nutrition Corp. dba: Viva Life Science, Inc.
Letter data
- Company
- Westar Nutrition Corp. dba: Viva Life Science, Inc.
- Recipient
- Westar Nutrition Corp. dba: Viva Life Science, Inc. | United States
- Issue date
- 2018-06-13
- Posted date
- Not available
- FDA office
- United States
- Subject
- Not available
- Product
- Not available
- CMS ID
- Not available
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Westar Nutrition Corp. dba: Viva Life Science, Inc.
June 13, 2018
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Recipient:
Westar Nutrition Corp. dba: Viva Life Science, Inc.
United States
Issuing Office:
United States
Office of Human and Animal Foods Division West 5
Los Angeles District Office
19701 Fairchild, Irvine, CA 92612
Telephone: 949-608-4496
UNITED PARCEL SERVICE
SIGNATURE REQUIRED
June 13, 2018
Emmanuel W. Fan, President/CEO
Westar Nutrition Corp. dba Viva Life Science, Inc.
350 Paularino Ave.
Costa Mesa, CA 92626
RE: WL #30-15 Close-Out Letter
Dear Mr. Fan:
The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter #30-15, dated July 22, 2015. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Sergio Chavez
Director Compliance Branch
Food and Drug Administration
HAF Division West 5
Content current as of:
06/21/2018